Meta-Analysis Dataset: Effectiveness of HIV Pre-Exposure Prophylaxis (PrEP) Across 100 Studies (2000–2025)

The included studies represent a mix of randomized controlled trials (62 studies) and observational studies (38 studies) conducted globally, encompassing diverse populations at heightened risk of HIV infection: • Men who have sex with men (MSM) (42 studies) • Serodiscordant couples (18 studies) • People who inject drugs (PWID) (12 studies) • High-risk heterosexuals (28 studies) PrEP interventions covered in the analysis include both oral formulations (84 studies) and long-acting injectable cabotegravir (CAB) (16 studies).

The study adhered to PRISMA guidelines for systematic review and meta-analysis. A total of 2,134 records were initially identified, with 100 studies meeting inclusion criteria after full-text screening. Outcomes assessed include: • HIV incidence reduction (relative risk, confidence intervals) • PrEP adherence metrics (pill count, electronic monitoring, plasma levels, self-report) • Safety and tolerability outcomes (GI events, renal function, bone density, injection-site reactions) • Risk of bias assessment using the Cochrane tool (for RCTs) and Newcastle-Ottawa Scale (for observational studies).